A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY PARKINSON'S DISEASE

Registry ID

PD0053

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

UCB INC

Start date

2021-03-31

Last update

2021-02-02

Conditions

• PARKINSON'S DISEASE

Related clinical trials

• A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY STAGE PARKINSON’S DISEASE
• FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF INTRATHECALLY ADMINISTERED ALN-SNCA IN PARTICIPANTS WITH EARLY PARKINSON¿S DISEASE
• PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF MIDBRAIN DOPAMINERGIC NEURONAL CELL THERAPY (BEMDANEPROCEL) FOR PARTICIPANTS WITH PARKINSON'S DISEASE
• TALLMAN FAMILY ENERGIZES RESEARCH TO HELP ALLEVIATE NEUROINFLAMMATION IN PARKINSONS DISEASE-"TALLER THAN PD". A PHASE 2 FUTILLITY STUDY TO EVALUATE THE EFFICACY,SAFETY AND TOLERABILITY OF HYDROXYCHLOROQUINE IN SUBJECT WITH EARLY TREATED PARKINSON'S DISEASE
• A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON¿S DISEASE.
• PHASE 1 STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF HUMAN EMBRYONIC STEM CELL-DERIVED MIDBRAIN DOPAMINE NEURON CELL THERAPY (MSK-DA01) FOR ADVANCED PARKINSON¿S DISEASE (STEM-PARKINSONS)

View on source registry